MoonLake Immunotherapeutics Presents 12-Week Data From The Phase 2 Mira Trial With Nanobody Sonelokimab For Hidradenitis Suppurativa At The European Academy Of Dermatology And Venereology Congress
Portfolio Pulse from Benzinga Newsdesk
MoonLake Immunotherapeutics (NASDAQ:MLTX) has presented positive 12-week data from its Phase 2 MIRA trial of Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress. The trial met its primary endpoint with a significantly higher proportion of patients treated with sonelokimab achieving HiSCR75 compared to those on placebo. The safety profile of sonelokimab was consistent with previously reported studies. The company anticipates 24-week data from the trial imminently.
October 11, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics' positive 12-week data from its Phase 2 MIRA trial of Sonelokimab could potentially boost investor confidence in the company's ability to develop effective treatments for inflammatory diseases.
The positive 12-week data from the Phase 2 MIRA trial of Sonelokimab indicates that the drug is effective and safe, which could potentially lead to regulatory approval and commercialization. This could increase the company's revenues and profitability, thereby positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100